The FDA is expected to approve the first generic version of the drug called Ganoderma lucidum (GLX-10) later this month.
The drug is based on the chemical structure of a fungus called Gans-D, and it’s designed to treat kidney stones and other chronic kidney disease conditions.
Gansdronium lucidorum (GLY-10), a similar drug, is expected in late 2018.
But the FDA is not required to approve GLX-11, or the new version of GLX that uses a synthetic version of Ganodermataceae.
GLX was approved by the FDA for the treatment of the disease of chronic kidney failure in March 2017.
GLY-11 is a different drug with a synthetic structure that has been approved by two different FDA panels.
That drug was approved for chronic kidney insufficiency in September 2017.
The FDA expects GLX to be approved within the next three months.
The drug will be given to people with kidney disease and other conditions that cause painful or unusual urination, and to people who are not otherwise able to get adequate care from their doctors.
The drugs are meant to help patients with kidney stones, kidney failure, and kidney stone infections.
The American College of Emergency Physicians (ACEP) estimates that about one in five people over the age of 60 in the United States will develop a new chronic kidney ailment in their lifetime.
The group says that as of 2016, about two million people in the U.S. had a kidney stone.
GLx-10 will be approved by a panel of the Food and Drug Administration.
GL-10 is expected for the same time frame as GLX.
The new drugs will not be available until late 2020, the group said in a statement.
The FDA is also expected to begin the process of approving the first-ever generic version for a drug called Ginseng lucidor, which is being developed to treat gout and other inflammatory conditions.
The company is planning to market the drug by the end of 2018.